42 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
8 Jan 24
Regulation FD Disclosure
7:30am
potential best-in-class Topolx Improved in vitro cytotoxicity, bystander effect and immunogenic cell death vs Dxd and SN-38 Conjugation Chemical, non … Annual J.P. Morgan Healthcare Conference January 8, 2024
Superior Bystander Activity vs. DS-1062 Superior Immunogenic Cell Death with Topolx Compared
8-K
EX-99.1
wa9t0lo
27 Sep 23
Regulation FD Disclosure
6:58am
8-K
EX-99.1
siklg1460 6ddq58149
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
8-K
EX-99.1
wwjux4
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
10-Q
EX-10.18
v2mpaxn1u23gdyeqspfh
9 Nov 22
Quarterly report
4:19pm
10-Q
mke6allz08bbvj qmum
9 Nov 22
Quarterly report
4:19pm
424B4
2si8yot5tz4 8cz443v4
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
2hepkqmhu046z5 4qg9
20 Oct 22
IPO registration (amended)
10:00am
S-1
81aelmg n0y99
18 Oct 22
IPO registration
4:03pm
S-8
EX-4.2
rghtuz
11 Oct 22
Registration of securities for employees
4:31pm
DRS
fvo41xox
11 Oct 22
Draft registration statement
12:00am
8-K
EX-3.1
jho5xsjqa02l7l3st xv
3 Oct 22
Changes in Control of Registrant
5:21pm